Mark joined the Foundation in 2012 as Consultant in Public Health Medicine/Programme Director and was appointed Director in October 2017. He leads the corporate development and strategic management of the Foundation and is responsible for the delivery of its work programme.
Mark graduated in medicine from the University of Edinburgh in 1992 and trained in general practice. Following a post as District Medical Officer in the Caribbean, he returned to the UK to train in public health medicine. Appointed NHS Consultant in Public Health Medicine in 2005, Mark has considerable experience in the NHS. His special interests include the evaluation and regulation of genetic tests and biomarkers and the commissioning of clinical genetics services.
He is the public health advisor to the NHS UK Genetic Testing Network (UKGTN) and a standing member of the Diagnostics Advisory Committee (DAC) of the National Institute for Health and Care Excellence (NICE) since 2010. He was appointed Chair of the DAC in October 2017.
Mark is an Honorary Visiting Fellow at the Institute of Public Health (University of Cambridge) and an accredited clinical supervisor for the HEE East of England Public Health Training Programme.
Hall A, Finnegan T, Chowdhury S, Dent T, Kroese M, Burton H. J Community Genet. 2018. https://doi.org/10.1007/s12687-018-0358-4. [Epub ahead of print]
Chitty LS, Wright D, Kroese M. et al Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down’s syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units BMJ. 2016 Jul 4;354:i3426.
Warren-Gash C, Kroese M, Burton H, Pharoah P. Implications of using whole genome sequencing to test unselected populations for high risk breast cancer genes: a modelling study Hered Cancer Clin Pract. 2016 Jun 1;14:12.
Chitty LS, Kroese M. Realising the promise of non-invasive prenatal testing. BMJ. 2015 Apr 10;350:1792.
Sagoo GS, Mohammed S, Barton G,…. Kroese M. Cost Effectiveness of Using Array-CGH for Diagnosing Learning Disability, Applied Health Economics and Health Policy. 2015,13,4, 421-432.
Borry P, Cornel M, Kroese M, Severin F. Points to consider for prioritizing clinical genetic testing services:a European consensus process oriented accountability for reasonableness European Journal of Human Genetics. 2014 Sept 24
Boustred C, Chitty L, Daley R, Fisher J, Hill M, Howarth A, Kroese M, Lench N, Lewis C, Lo K, Mason S, Mckay F, Morris S, Plagnol V, Spencer K, wright D. Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol BMC Pregnancy Childbirth. 2014 Jul 16;14:229
Alberg C, Burton H, Kroese M, Lakshman R, Whittaker J. A framework for the prioritization of investment in the provision of genetic tests Public Health Genomics. 2010 13 (7-8) 538-43
Kroese M, Wright C. Evaluation of genetic tests for susceptibility to common complex diseases: why, when and how? Human Genetics. 2009; doi:10.1007/s00439-009-0767-x
Kroese M, Zimmern RL, Farndon P, Stewart F, Whittaker J. How can genetic tests be evaluated for clinical use? Experience of the UK Genetic Testing Network. Eur J Hum Genet. 2007;15:917-21.
Burke W, Kroese M, Zimmern R. Defining purpose: a key step in genetic test evaluation Genetics in Medicine. 2007 9(10):675-681
Kroese M, Pinder S, Zimmern R. HER2 status in breast cancer - an example of pharmacogenetic testing Journal of the Royal Society of Medicine. 2007 Jul;100(7):326-9
Brice P, Burton H, Higgins J, Sagoo G, Sanderson S, Subramonia-Iyer S. Array-based comparative genomic hybridisation for investigating chromosomal abnormalities in patients with learning disability: meta-analysis of diagnostic and false positive yields Genetics In Medicine. 2006
Emery J, Higgins J, Kroese M, Patch C, Sanderson S, Zimmern R. How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom Genetics in Medicine. 2005;7(7):495-500